A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance

In April 2013 our group published a review on predictive molecular pathology in this journal. Although only 2 years have passed many new facts and stimulating developments have happened in diagnostic molecular pathology rendering it worthwhile to present an up-date on this topic. A major technical improvement is certainly given by the introduction of next-generation sequencing (NGS; amplicon, whole exome, whole genome) and its application to formalin-fixed paraffin-embedded (FFPE) tissue in routine diagnostics. Based on this ‘revolution’ the analyses of numerous genetic alterations in parallel has become a routine approach opening the chance to characterize patients’ malignant tumors much more deeply without increasing turn-around time and costs. In the near future this will open new strategies to apply ‘off-label’ targeted therapies, e.g. for rare tumors, otherwise resistant tumors etc. The clinically relevant genetic aberrations described in this review include mutation analyses of RAS (KRAS and NRAS), BRAF and PI3K in colorectal cancer, KIT or PDGFR alpha as well as BRAF, NRAS and KIT in malignant melanoma. Moreover, we present several recent advances in the molecular characterization of malignant lymphoma. Beside the well-known mutations in NSCLC (EGFR, ALK) a number of chromosomal aberrations (KRAS, ROS1, MET) have become relevant. Only very recently has the clinical need for analysis of BRCA1/2 come up and proven as a true challenge for routine diagnostics because of the genes’ special structure and hot-spot-free mutational distribution. The genetic alterations are discussed in connection with their increasingly important role in companion diagnostics to apply targeted drugs as efficient as possible. As another aspect of the increasing number of druggable mutations, we discuss the challenges personalized therapies pose for the design of clinical studies to prove optimal efficacy particularly with respect to combination therapies of multiple targeted drugs and conventional chemotherapy. Such combinations would lead to an extremely high complexity that would hardly be manageable by applying conventional study designs for approval, e.g. by the FDA or EMA. Up-coming challenges such as the application of methylation assays and proteomic analyses on FFPE tissue will also be discussed briefly to open the door towards the ultimate goal of reading a patients' tissue as ‘deeply’ as possible. Although it is yet to be shown, which levels of biological information are most informative for predictive pathology, an integrated molecular characterization of tumors will likely offer the most comprehensive view for individualized therapy approaches. To optimize cancer treatment we need to understand tumor biology in much more detail on morphological, genetic, proteomic as well as epigenetic grounds. Finally, the complex challenges on the level of drug design, molecular diagnostics, and clinical trials make necessary a close collaboration among academic institutions, regulatory authorities and pharmaceutical companies.

[1]  Jeffrey W. Clark,et al.  Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Didier Frappaz,et al.  Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[4]  Ralf Herwig,et al.  Targeted high throughput sequencing in clinical cancer Settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity , 2011, BMC Medical Genomics.

[5]  Razelle Kurzrock,et al.  Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative , 2012, Clinical Cancer Research.

[6]  G. Reifenberger,et al.  Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[7]  L. Buturovic,et al.  Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens. , 2011, The Journal of molecular diagnostics : JMD.

[8]  Kikuya Kato,et al.  Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib , 2008, Cancer science.

[9]  M. Halks-Miller,et al.  A Multicenter Study Directly Comparing the Diagnostic Accuracy of Gene Expression Profiling and Immunohistochemistry for Primary Site Identification in Metastatic Tumors , 2013, The American journal of surgical pathology.

[10]  N. Pavlidis,et al.  Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors. , 2009, Seminars in oncology.

[11]  A. Warth,et al.  [Novel morphological and molecular aspects of lung cancer]. , 2013, Der Pathologe.

[12]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[13]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[14]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[15]  D. Zuo,et al.  ErbB Receptors as Prognostic and Therapeutic Drug Targets in Bone and Soft Tissue Sarcomas , 2014, Cancer investigation.

[16]  D. Reed,et al.  Advances in Therapy for Pediatric Sarcomas , 2014, Current Oncology Reports.

[17]  F. Collins,et al.  First FDA authorization for next-generation sequencer. , 2013, The New England journal of medicine.

[18]  T. Nielsen,et al.  Cancer genomics: why rare is valuable , 2015, Journal of Molecular Medicine.

[19]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[20]  Marc Ladanyi,et al.  EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics , 2013, Molecular Cancer Therapeutics.

[21]  E. Smit,et al.  VeriStrat® has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib , 2012, British Journal of Cancer.

[22]  Jan Budczies,et al.  Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing. , 2015, Lung cancer.

[23]  Sabine Tejpar,et al.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.

[24]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[25]  Helen X. Chen,et al.  Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group , 2015, Pediatric blood & cancer.

[26]  R. Kreitman,et al.  Molecular variant of hairy cell leukemia with poor prognosis , 2011, Leukemia & lymphoma.

[27]  M. Driscoll,et al.  Melanoma epidemic: Facts and controversies. , 2010, Clinics in dermatology.

[28]  R. Labianca,et al.  Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  N. Pavlidis,et al.  Switching benchmarks in cancer of unknown primary: from autopsy to microarray. , 2007, European journal of cancer.

[30]  D. Catovsky,et al.  The variant form of hairy-cell leukaemia. , 2003, Best practice & research. Clinical haematology.

[31]  Ulrich Keilholz,et al.  The combinatorial complexity of cancer precision medicine , 2014, Oncoscience.

[32]  Marc Ladanyi,et al.  Advances in sarcoma genomics and new therapeutic targets , 2011, Nature Reviews Cancer.

[33]  N. Pavlidis,et al.  Carcinoma of Unknown Primary (CUP) , 2014 .

[34]  K. Young,et al.  Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Cassandra Willyard 'Basket studies' will hold intricate data for cancer drug approvals , 2013, Nature Medicine.

[36]  S. Barrans,et al.  Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  M. Tronnier,et al.  Cancer Management and Research Dovepress Treating Advanced Melanoma: Current Insights and Opportunities , 2022 .

[38]  R. Aharonov,et al.  A second-generation microRNA-based assay for diagnosing tumor tissue origin. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Jeffrey W. Clark,et al.  Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. , 2011, The Lancet. Oncology.

[40]  A. McKenna,et al.  The genomic landscape of pediatric Ewing sarcoma. , 2014, Cancer discovery.

[41]  D. Maintz,et al.  Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib. , 2013, Lung cancer.

[42]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[43]  Marius Ilie,et al.  Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? , 2014, Annals of translational medicine.

[44]  M. Heinrich,et al.  PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  T. Stinchcombe Novel agents in development for advanced non-small cell lung cancer , 2014, Therapeutic advances in medical oncology.

[46]  Dirk Schadendorf,et al.  Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. , 2014, The Lancet. Oncology.

[47]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[48]  Robert Brian Jenkins,et al.  Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[49]  C. Antonescu,et al.  Long-term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor: ACOSOG Z9000 (Alliance) Intergroup Phase 2 Trial , 2013, Annals of surgery.

[50]  R. Foà,et al.  Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. , 2012, Blood.

[51]  J. Lanchbury,et al.  BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. , 2012, Gynecologic oncology.

[52]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[53]  T. Kohno,et al.  Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers , 2014, Modern Pathology.

[54]  G. Getz,et al.  Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. , 2014, Cancer discovery.

[55]  Carsten Denkert,et al.  PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[57]  D. Matei,et al.  Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[58]  C. Bokemeyer,et al.  Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. , 2012, European journal of cancer.

[59]  F. Speleman,et al.  Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. , 2006, Human molecular genetics.

[60]  W. Weichert,et al.  Neue morphologische und molekulare Aspekte des Lungenkarzinoms , 2013, Der Pathologe.

[61]  D. Schadendorf,et al.  BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management. , 2014, Chinese clinical oncology.

[62]  Shreyaskumar R Patel Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance. , 2012, Cancer treatment reviews.

[63]  R. Greil,et al.  The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer , 2014, Clinical Cancer Research.

[64]  Ju-Han Lee,et al.  Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis. , 2013, Journal of gastrointestinal and liver diseases : JGLD.

[65]  Jan Bogaerts,et al.  Designing transformative clinical trials in the cancer genome era. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  R. Gascoyne,et al.  MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.

[67]  M. Erlander,et al.  Blinded comparator study of immunohistochemical analysis versus a 92-gene cancer classifier in the diagnosis of the primary site in metastatic tumors. , 2013, The Journal of molecular diagnostics : JMD.

[68]  R. Govindan,et al.  Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  D. Louis WHO classification of tumours of the central nervous system , 2007 .

[70]  Shuxia Zhao,et al.  Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. , 2013, Cancer discovery.

[71]  U. Dirksen,et al.  Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma , 2015, Clinical Cancer Research.

[72]  G. Rigakos,et al.  BRCAness: finding the Achilles heel in ovarian cancer. , 2012, The oncologist.

[73]  R. Mehra,et al.  Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer , 2014, Cancer Chemotherapy and Pharmacology.

[74]  S. Woodman,et al.  Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type , 2009, Modern Pathology.

[75]  P. Hogendoorn,et al.  Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes , 2015, International journal of molecular sciences.

[76]  Pieter Wesseling,et al.  International Society of Neuropathology‐Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading , 2014, Brain pathology.

[77]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[78]  J. Friedberg Double-hit diffuse large B-cell lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  E. Shaw,et al.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[81]  W. Choi,et al.  MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. , 2013, Blood.

[82]  A. Ribas,et al.  Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  S. Powell,et al.  BRCA1 and BRCA2: different roles in a common pathway of genome protection , 2011, Nature Reviews Cancer.

[84]  R. Greil,et al.  A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors , 2011, Clinical Cancer Research.

[85]  D De Ruysscher,et al.  Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[86]  M. Raffeld,et al.  Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. , 2012, Blood.

[87]  J. Yahalom,et al.  Alternatives in the Management of Gastric Lymphoma. , 1991, Leukemia & lymphoma.

[88]  P. Jain,et al.  Novel therapeutic options for relapsed hairy cell leukemia , 2015, Leukemia & lymphoma.

[89]  A. Voigt,et al.  Analysis of EPCAM protein expression in diagnostics of Lynch syndrome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  C. Antonescu,et al.  Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.

[91]  J. Blay,et al.  Adherence to imatinib therapy in patients with gastrointestinal stromal tumors. , 2014, Cancer treatment reviews.

[92]  M. Dietel,et al.  EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations , 2012, Virchows Archiv.

[93]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[94]  Li Ding,et al.  Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. , 2014, Cancer discovery.

[95]  L. Staudt,et al.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  L. Staudt,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[97]  A. Saven,et al.  Hairy cell leukemia: an update. , 2003, Current opinion in hematology.

[98]  William Pao,et al.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.

[99]  C. Ng,et al.  NRAS mutation status is an independent prognostic factor in metastatic melanoma , 2012, Cancer.

[100]  L. Staudt,et al.  Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.

[101]  Bert Vogelstein,et al.  DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES , 2014 .

[102]  C. Dooms,et al.  Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  S N Thibodeau,et al.  Microsatellite instability in cancer of the proximal colon. , 1993, Science.

[104]  J. George,et al.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  Geoffrey R. Oxnard,et al.  Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer , 2013, Science Translational Medicine.

[106]  A. Marchetti,et al.  Guideline on the requirements of external quality assessment programs in molecular pathology , 2012, Virchows Archiv.

[107]  Winand N M Dinjens,et al.  Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  J. Hainsworth,et al.  Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology. , 2013, Journal of the National Cancer Institute.

[109]  R. Greil,et al.  The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients , 2013, British Journal of Cancer.

[110]  Narasimhan P. Agaram,et al.  Novel V600E BRAF mutations in imatinib‐naive and imatinib‐resistant gastrointestinal stromal tumors , 2008, Genes, chromosomes & cancer.

[111]  R. Greil,et al.  Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[112]  Darryl Shibata,et al.  Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis , 1993, Nature.

[113]  B. Vogelstein,et al.  Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. , 1994, The American journal of pathology.

[114]  S. Treon,et al.  Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. , 2014, Blood.

[115]  Li Ding,et al.  Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. , 2014, Cell reports.

[116]  D. Matei,et al.  Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. , 2012, The New England journal of medicine.

[117]  J. Blay,et al.  KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. , 2006, European journal of cancer.

[118]  E. Musulen,et al.  Gastrointestinal stromal tumors , 2006, Abdominal Imaging.

[119]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[120]  C. Tibaldi Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small-cell lung cancer. , 2014, Pharmacogenomics.

[121]  R. Salunga,et al.  Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. , 2009, Archives of pathology & laboratory medicine.

[122]  M. Heinrich,et al.  Molecular pathobiology of gastrointestinal stromal sarcomas. , 2008, Annual review of pathology.

[123]  Mark Rosenzweig,et al.  Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. , 2015, Cancer discovery.

[124]  Kai Fu,et al.  Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[125]  M Hummel,et al.  Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance , 2013, Cancer Gene Therapy.

[126]  A. von Deimling,et al.  Validation of a Manual Protocol for BRAF V600E Mutation-specific Immunohistochemistry , 2015, Applied immunohistochemistry & molecular morphology : AIMM.

[127]  Tatiana G. Kutateladze,et al.  Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[128]  Christopher H. Schmid,et al.  Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research. , 2013, Journal of clinical epidemiology.

[129]  R. Doebele,et al.  The Minority Report: Targeting the Rare Oncogenes in NSCLC , 2014, Current Treatment Options in Oncology.

[130]  H. Höfler,et al.  Multicenter Immunohistochemical ALK-Testing of Non–Small-Cell Lung Cancer Shows High Concordance after Harmonization of Techniques and Interpretation Criteria , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[131]  R. Gray,et al.  Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. , 2007, Journal of the National Cancer Institute.